Lung adenocarcinoma (LUAD), the most common histological subtype of NSCLC, is a genetically heterogeneous disease that can be classified into molecular subtypes based on mutational drivers including tyrosine kinases (EGFR, ALK, ROS1, NTRK, RAF, MET, and RET) that can be targeted rationally using the 17 FDA‐approved tyrosine kinase inhibitors (TKIs), as well as KRAS, a common NSCLC molecular subtype with limited treatment options currently.2, 3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.